← All status records
Educational regulatory-status record
Retatrutide outside an authorized approval record
Unauthorized pathway warning
This page explains an official classification boundary. It is not a recommendation, suitability assessment, or commercial listing.
Official status explanation
FDA states that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law. This page records the agency warning as an educational boundary, not as a product directory.
Record freshness: within the review interval · last reviewed 2026-08-18 · review due 2026-09-17
What this record does not conclude
- It does not identify or link to a seller, source, or product listing.
- It does not establish a safe, lawful, or appropriate way for a person to obtain or use it.
- It does not replace current agency notices or jurisdiction-specific legal review.
Source and review trail
- Source
- FDA concerns with unapproved GLP-1 drugs used for weight loss
- Source type
- FDA
- Source date
- Page current as checked
- Checked
- 2026-08-18
- Review rule
- Human review required within 30 days and after material official change.
There are no vendors, purchase links, product destinations, or personalized selection tools on this educational page.